Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Cleaves the vWF multimers in plasma into smaller forms.
Plasma. Expressed primarily in liver.
Involvement in disease
Defects in ADAMTS13 are the cause of thrombotic thrombocytopenic purpura congenital (TTP) [MIM:274150]; also known as Upshaw-Schulman syndrome (USS). A hematologic disease characterized by hemolytic anemia with fragmentation of erythrocytes, thrombocytopenia, diffuse and non-focal neurologic findings, decreased renal function and fever.
The pro-domain is not required for folding or secretion and does not perform the common function of maintening enzyme latency. The spacer domain is necessary to recognize and cleave vWF. The C-terminal TSP type-1 and CUB domains may modulate this interaction.
May contain a C-mannosylation site and O-fucosylation sites in the TSP type-1 domains. The precursor is processed by a furin endopeptidase which cleaves off the pro-domain.
A disintegrin and metalloproteinase with thrombospondin motifs 13 antibody
A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 13 antibody
A disintegrin like and metalloprotease with thrombospondin type 1 motif 13 antibody
ADAM metallopeptidase with thrombospondin type 1 motif 13 antibody
ADAM TS antibody
ADAM-TS 13 antibody
ADAMTS 13 antibody
ADAMTS13 protein antibody
Von Willebrand factor cleaving protease antibody
von Willebrand factor-cleaving protease antibody
vWF cleaving protease antibody
vWF CP antibody
vWF-cleaving protease antibody
Immunoprecipitation - ADAMTS13 antibody (ab72335)
Immunoprecipitation/ Western Blot of ADAMTS13.
Lane 1: ab72335.
Lane 2: Control IgG.
ab72335 at 1µg/ml for WB.
Pooled normal human serum at 300µl/IP, 10% of IP loaded.
Chemiluminescence with an exposure time of 30 seconds.
Note: The antibody was conjugated to agarose to produce agarose immobilized antibody. Used at 35µg of antibody per IP.